Share on LinkedInShare on LinkedIn

ARTICLE · 29 DECEMBER 2016

Biosimilars: Solicitor General Recommends Granting Certiorari In Amgen v. Sandoz

The Supreme Court deferred its decision on the parties' certiorari petitions in order to consider the Solicitor General's views.

United StatesIntellectual Property

Responding to the Supreme Court's request for its views, see prior post, the Solicitor General recently recommended granting certiorari and reversing some of the Federal Circuit's key holdings in Amgen v. Sandoz (Nos. 15-1039 & 15-1195). 

The case involves issues central to the application of the Biologics Price Competition and Innovation Act of 2009 (BPCIA), the statutory scheme establishing an abbreviated pathway for regulatory approval of follow-on biologic products. The Federal Circuit held, first, that a biosimilar applicant cannot provide the statutory 180-day notice of commercial marketing until after the biosimilar's approval by the FDA and, second, that a biosimilar applicant is not required to engage in the so-called "patent dance" and disclose information—such as its aBLA and manufacturing information—to the original biologic manufacturer. More information on the Federal Circuit's decision can be found here and here.  The Supreme Court deferred

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from